Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic ph...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:RMD Open
Asıl Yazarlar: Cappelli, Laura C, Shah, Ami A, Bingham, Clifton O
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2016
Konular:
Autoimmunity
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051426/
https://ncbi.nlm.nih.gov/pubmed/27752360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000321
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller